170486 ⎘
Assays involving biological materials from specific organisms or of a specific nature from animals; from humans; Assays involving receptors, cell surface antigens or cell surface determinants; Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3 Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISEASES
#2CONTROL CELL POPULATIONS FOR DETECTION OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
#3ANTIBODIES FOR PLATELET FCyRIIA AND RELATED METHODS OF USE
#4APPLICATION OF BIOMARKER IN PREPARING METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE CLASSIFICATION PRODUCTS
#5ANTI-FCRN ANTIBODIES
#6COMPOSITIONS AND METHODS FOR ASSAYING PLATELET REACTIVITY AND TREATMENT SELECTION
#7Compositions and Methods for NK-92 Cells Expressing Native CD16
#8METHOD OF MEASURING LEVEL OF IMMUNE SUPPRESSION
#9ESTIMATING CELLULAR POPULATIONS
#10METHOD FOR PERFORMING EARLY DIAGNOSIS OF SEPSIS USING ANALYSIS DEVICE INCLUDING MICRO FILTER
#11CHARACTERIZATION OF BINDING-RELATED CQAS IN THEREAPEUTIC MABS
#12AFFINITY CHROMATOGRAPHY LIGANDS FOR ANTIBODY GLYCOVARIANT SEPARATION
#13AFUCOSYLATION OF HLA-SPECIFIC IGG1 AS A POTENTIAL PREDICTOR OF ANTIBODY PATHOGENICITY IN KIDNEY TRANSPLANTATION
#14DIAGNOSTIC, PROGNOSTIC, THERAPEUTIC AND SCREENING PROTOCOLS
#15BINDING PROTEINS SPECIFIC FOR CD32A
#16METHODS FOR SELECTING A CANCER PATIENT FOR TREATMENT
#17METHOD FOR PREDICTING IN VIVO PHARMACOKINETICS OF MOLECULE
#18FLUID TRANSFER DEVICES WITH INTEGRATED FLOW-BASED ASSAY AND METHODS OF USING THE SAME FOR IDENTIFYING SEPSIS
#19METHOD FOR DETERMINING BASOPHIL ACTIVATION IN A SAMPLE
#20Methods for Categorizing and Treating Subjects at Risk for Pulmonary Exacerbation and Disease Progression
#21ANTIBODY BINDING TO FCRN FOR TREATING AUTOIMMUNE DISEASES
#22ASSAY METHOD OF ANTIBODY
#23HUMANIZED AND AFFINITY MATURED ANTIBODIES TO FcRH5 AND METHODS OF USE
#24BIODOSIMETRY PANELS AND METHODS
#25CD16 ANTIBODY AND USE THEREOF
#26SELECTION OF PATIENTS FOR COMBINATION THERAPY
#27IN VITRO CELL-BASED ASSAY FOR PREDICTING PHARMACOKINETICS AND BRAIN PENETRATION OF BIOLOGICS
#28METHOD FOR RESOLVING COMPLEX, MULTISTEP ANTIBODY INTERACTIONS
#29METHODS AND COMPOSITIONS FOR THE TREATMENT OF CROHN'S DISEASE
#30Compositions and methods for assaying platelet reactivity and treatment selection
#31IMMUNOGLOBULIN EXPRESSION LEVELS AS BIOMARKER FOR PROTEASOME INHIBITOR RESPONSE
#32ESTIMATING CELLULAR POPULATIONS
#33LARGE MOLECULE UNSPECIFIC CLEARANCE ASSAY
#34METHOD FOR DETECTION OF CD16B
#35Anti-FcRn Antibodies
#36METHODS FOR PREDICTING THERAPEUTIC BENEFIT OF ANTI-CD19 THERAPY IN PATIENTS
#37Methods for categorizing and treating subjects having cystic fibrosis (CF) and at risk for severe pulmonary exacerbation
#38POTENCY ASSAYS FOR ANTIBODY DRUG SUBSTANCE BINDING TO AN FC RECEPTOR
#39Humanized and affinity matured antibodies to FcRH5 and methods of use
#40METHOD FOR EVALUATING THE PRESENCE OF A VIRAL RESERVOIR, AND EVALUATING THE EFFICACY OF A DRUG AGAINST SAID RESERVOIR
#41Biomarkers for the diagnosis of invasive fungal infections
#42Method for assisting prediction of exacerbation of respiratory infection, and device to assist in predicting exacerbation of respiratory infection
#43Method for the evaluation of antiretroviral therapy (ART) effectiveness in HIV-1 CD4+CD89+ cellular reservoirs
#44Selection of patients for combination therapy
#45IMMUNOGLOBULIN EXPRESSION LEVELS AS BIOMARKER FOR PROTEASOME INHIBITOR RESPONSE
#46COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISEASES
#47Compositions and methods for predicting post-surgical cardiovascular events
#48METHOD AND APPARATUS FOR MONITORING THE STATE OF HEALTH OF DAIRY COWS
#49ANTIGEN-BINDING MOLECULE FOR ELIMINATING AGGREGATED ANTIGENS
#50Systems and methods for determining a chemical state
#51Immunoglobulin Expression Levels as Biomarker for Proteasome Inhibitor Response
#52Dosimeters including lensless imaging systems
#53Methods for Categorizing and Treating Subjects at Risk for Pulmonary Exacerbation and Disease Progression
#54Compositions and methods for assaying platelet reactivity and treatment selection
#55Methods for Diagnosing and Treating Subjects for Pulmonary Exacerbation
#56Antibody binding to FCRN for treating autoimmune diseases
#57Method for isolating HIV reservoir cells expressing CD32a cell marker
#58Biodosimetry panels and methods
#59METHODS AND KITS FOR DETECTING BASOPHIL ACTIVATION
#60METHODS FOR IMPROVING FERTILITY IN ARTIFICIAL INSEMINATION
#61Diagnostic, prognostic, therapeutic and screening protocols
#62Humanized and affinity matured antibodies to FcRH5 and methods of use
#63Anti-FcRn antibodies
#64Method for the detection of cells associated with the latent HIV viral reservoir using membrane biomarkers
#65METHODS FOR PREDICTING THERAPEUTIC BENEFIT OF ANTI-CD19 THERAPY IN PATIENTS
#66ESTIMATING CELLULAR POPULATIONS
#67Humanized affinity matured anti-FcRn antibodies
#68Methods for categorizing and treating subjects at risk for pulmonary exacerbation and disease progression
#69Systems and methods for determining a chemical state
#70Method for producing soluble FcR as Fc-fusion with inert immunoglobulin Fc-region and uses thereof
#71Biodosimetry panels and methods
#72KITS, COMPOSITIONS AND METHODS FOR DETECTING A BIOLOGICAL CONDITION
#73Method and apparatus for monitoring the state of health of dairy cows
#74Methods of diagnosing infection or recurrence in a subject
#75Multiples multiplex immunohistochemical assay using primary antibodies of the same host species
#76Polymeric Fc proteins and methods of screening to alter their functional characteristics
#77Systems and Methods for Detecting a Biological Condition
#78POTENCY ASSAYS FOR ANTIBODY DRUG SUBSTANCE BINDING TO AN FC RECEPTOR
#79Systems and methods for determining a chemical state
#80Multiplex immunohistochemical assay using primary antibodies of the same host species
#81Antibody binding to FcRn for treating autoimmune diseases
#82Pharmaceutical composition for preventing or treating neurodegenerative diseases
#83METHODS AND COMPOSITIONS FOR TREATMENT OF MACROPHAGE-RELATED DISORDERS
#84Methods for diagnosing and treating subjects for pulmonary exacerbation
#85Humanized and affinity matured antibodies to FcRH5 and methods of use
#86BIOMARKERS FOR MULTIPLE MYELOMA
#87Immunohistochemical assay for detection of CD3 and CD16
#88Microfluidic system and method for isolating and quantifying at least one sub-population of cells from a population of cells
#89Immunoglobulin expression levels as biomarker for proteasome inhibitor response
#90Kits, compositions and methods for detecting a biological condition
#91FcRn-specific human antibody and composition for treatment of autoimmune diseases
#92Peptide for inducing mast cell-specific apoptosis and use thereof
#93ALBUMIN VARIANTS BINDING TO FCRN
#94Biodosimetry panels and methods
#95BIOMARKERS OF AUTOIMMUNE AND/OR CHRONIC DISEASES ASSOCIATED WITH JOINT INFLAMMATION
#96ANTIGEN-BINDING MOLECULE FOR ELIMINATING AGGREGATED ANTIGENS
#97Diagnostic, prognostic, therapeutic and screening protocols
#98SYSTEMS AND METHODS FOR DETECTING A BIOLOGICAL CONDITION
#99Method for treating pulmonary exacerbation and disease progression in subjects having cystic fibrosis
#100Systems and methods for determining a chemical state
#101Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds
#102Systems and methods for detecting a biological condition
#103Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same
#104DIAGNOSIS AND TREATMENT OF ASPIRIN-EXACERBATED RESPIRATORY DISEASE (AERD)
#105Anti-thrombotic compositions and methods for assaying platelet reactivity and treatment selection
#106CANCER PROGNOSTIC ASSAYS
#107Display of binding agents
#108Method for producing soluble FcR as Fc-fusion with inert immunoglobulin Fc-region and uses thereof
#109Kits, compositions and methods for detecting a biological condition
#110Anti-FcRn antibodies
#111BIOMARKERS AND TEST PANELS USEFUL IN SYSTEMIC INFLAMMATORY CONDITIONS
#112Isolated cells from humanized FcγR mice
#113Method for diagnosing breast cancer by detection of polymeric immunoglobulin receptor in vesicles isolated from patients
#114Predictive biomarker for cancer treatment with ADCC-enhanced antibodies
#115Detection of antibodies using an improved immune complex (IC) ELISA
#116FC RECEPTOR BINDING PROTEINS
#117Software integrated cytometric assay for quantification of the human polymorphonuclear leukocyte FCγRI receptor (CD64)
#118Identification and engineering of antibodies with variant FC regions and methods of using same
#119PROCESS FOR REGULATING IMMUNE RESPONSE
#120Humanized FcgR mice
#121HUMAN Fc GAMMA RECEPTOR III
#122Peptides that block the binding of IgG to FcRn
#123Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds
#124Cytokine production-inducing antibody
#125Blood monocyte CD163 expression as a biomarker in HIV-1 infection and neuroaids
#126Display of binding agents
#127IMMUNOMODULATORY PEPTIDES
#128Potency assays for antibody drug substance binding to an Fc receptor
#129Fc receptor binding proteins
#130Software integrated cytometric assay for quantification of the human polymorphonuclear leukocyte FcγRI receptor (CD64)
#131Method of analyzing lymphocytes
#132Methods of Identifying Antibodies to Ligands of Orphan Receptors
#133HUMAN Fc GAMMA RECEPTOR III
#134Identification and engineering of antibodies with variant Fc regions and methods of using same
#135Identification and engineering of antibodies with variant Fc regions and methods of using same
#136Treatment of atherosclerosis
#137Peptides that block the binding of IgG to FcRn
#138Human monoclonal antibodies to FC gamma receptor II (CD32)
#139Method to detect IgE
#140Methods of assessing susceptibility to drug-induced thrombocytopenia
#141CRYSTAL STRUCTURES AND MODELS FOR Fc RECEPTORS AND USES THEREOF IN THE DESIGN OR IDENTIFICATION OF Fc RECEPTOR MODULATOR COMPOUNDS
#142Tetrameric antibody complexes for blocking non-specific labeling of antigens
#143Method to decrease nonspecific staining by Cy5
#144Methods of identifying compounds that modulate igg mediated mast cell activation
#145Method to detect IgE
#146Method for determining a risk of atherosclerosis or future development of atherosclerotic complications
#147Method of measuring activation of effector cells
#148Treatment of inflammatory conditions
#149Method for measuring FceRII/CD23 IgE receptor in human feces as an indicator of a TH2 predominant immune response involved in gastrointestinal illnesses
#150Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds
#151Identification and engineering of antibodies with variant Fc regions and methods of using same
#152Biological markers for evaluating therapeutic treatment of inflammatory and autoimmune disorders